Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Ecor1 Capital
BioCentury | Feb 7, 2025
Finance
Strong demand for Sionna latest good sign for IPOs: Public Equity Report
Vertex competitor posts a first-day gain after an upsized offering; plus financings for Gh Research and Tectonic
BioCentury | Nov 8, 2024
Finance
Neurogene draws $200M PIPE ahead of next week’s Rett syndrome data
In BioCentury’s Finance Report: Travere’s follow-on, CrossBridge’s seed round among few fundings during quiet election week
BioCentury | Oct 8, 2024
Management Tracks
Veteran investor Oleg Nodelman joins Galapagos board
Plus: New CEOs at QuantX, Oak Hill, and updates from Every Cure, Mosaic, Anixa and more
BioCentury | Aug 16, 2024
Finance
Public Equity Report: AnaptysBio, Avidity draw nine-digit offerings
Plus: MeiraGTx, scPharmaceuticals each raise $50M
BioCentury | Jul 18, 2024
Finance
Venture Report: Five biotechs raise nearly $800M in two-day flurry
Plus: New capital for CytoReason, Truvian and Renalys
BioCentury | Jun 21, 2024
Finance
Public Equity Report: Cinclus dips after pricing Stockholm IPO
Plus: Tectonic arrives on NASDAQ; UroGen prices offering amid rolling NMIBC submission
BioCentury | May 31, 2024
Finance
Public Equity Report: Insmed, Merus raise combined $1B+ after readouts
Plus: PIPEs help Celcuity, Cargo advance clinical programs
BioCentury | May 24, 2024
Finance
Public Equity Report: Investors see Cytokinetics’ moves as doubt for M&A
Plus: IPO updates from Sunho, Rapport; Bicycle’s massive PIPE; Dyne’s opportunistic follow-on; and more
BioCentury | May 16, 2024
Finance
Venture Report: Blackstone eyes pipeline-in-a-product via Uniquity launch
Plus: New funds for Sands and NewVale, and series C rounds for Lycia and Ajax
BioCentury | May 9, 2024
Finance
Venture report: Big rounds for Bluejay, Attovia and Zenas
Strong fundraising week also included launches by Prologue and Commit, plus raises by Aardvark, Memo and OverT
Items per page:
1 - 10 of 198